Adamas Pharmaceuticals Inc., of Emeryville, Calif., appointed Neil McFarlane CEO and to its board. David Mahoney was appointed chair of its board.

Alexion Pharmaceuticals Inc., of Boston, appointed Aradhana Sarin chief financial officer.

ALK-Abello A/S, of Hørsholm, Denmark, proposed the election of Anders Hedegaard as chair of its board.

Alkermes plc, of Dublin, appointed Richard Gaynor and Frank Anders Wilson to its board.

Aristea Therapeutics, of San Diego, appointed Brian Kotzin, Jay Birnbaum, Michael Howell and Camilla Simpson to its scientific advisory board.

Bayer AG, of Leverkusen, Germany, appointed Daniella Foster head of public affairs and sustainability for the consumer health division.

Berkeley Lights Inc., of Emeryville, Calif., appointed Elizabeth Nelson to its board.

Black Diamond Therapeutics Inc., of Cambridge, Mass., appointed Thomas Leggett chief financial officer.

Corcept Therapeutics Inc., of Menlo Park, Calif., appointed Kimberly Park to its board.

Curis Inc., of Lexington, Mass., appointed Bill Steinkrauss chief financial officer.

Encoded Therapeutics Inc., of South San Francisco, appointed Andrew Stober chief manufacturing officer and David McNinch chief business officer.

Evelo Biosciences Inc., of Cambridge, Mass., appointed David Epstein chair of its board.

Everest Medicines Ltd., of Shanghai, appointed Jason Brown chief business officer, Frank Grams senior vice president of alliance management and head of business development in Europe, Sophia Zhu senior vice president of portfolio development and strategic planning, Alex Wang head of international business and Daniel Weng vice president of finance.

Gemini Therapeutics Inc., of Cambridge, Mass., appointed Jason Meyenburg CEO and to its board.

Gritstone Oncology Inc., of Emeryville, Calif., appointed Elaine V. Jones to its board.

I-Mab Biopharma (Shanghai) Co. Ltd., of Shanghai, appointed Neil K. Warma general manager of I-Mab Biopharma U.S.

Insitro Inc., of South San Francisco, appointed Matthew Rasmussen vice president of data engineering and Duane Valz general counsel.

Jounce Therapeutics Inc., of Cambridge, Mass., appointed Jacquelyn Fahey Sandell chief legal officer and corporate secretary.

Lysando AG, of Triesenberg, Liechtenstein, appointed Leonhard Stärk and Karl Liese to its ethical committee.

Neurocrine Biosciences Inc., of San Diego, appointed Leslie V. Norwalk to its board.

Nkarta Therapeutics Inc., of South San Francisco, appointed Nadir Mahmood chief business officer.

Novabay Pharmaceuticals Inc., of Emeryville, Calif., appointed Jeff Zheng to its board. He will chair the nominating and corporate governance committee and will serve on the audit and compensation committees.

Oculis SA, of Lausanne, Switzerland, appointed Eric Donnenfeld and Ramin Tadayoni to its scientific advisory board.

Opiant Pharmaceuticals Inc., of Santa Monica, Calif., appointed Aziz Mottiwala chief commercial officer and Rahsaan Thompson general counsel.

Pulmotect Inc., of Houston, appointed Kumar Srinivasan to its board.

Rallybio Inc., of Farmington, Conn., appointed Douglas Sheridan to its leadership team.

Salarius Pharmaceuticals Inc., of Houston, appointed Scott Jordan chief business officer and Mark Rosenblum executive vice president finance and interim chief financial officer.

Soligenix Inc., of Princeton, N.J., appointed Daniel P. Ring vice president of business development and strategic planning.

SQZ Biotechnologies Inc., of Watertown, Mass., appointed Lawrence Knopf general counsel.

Verve Therapeutics Inc., of Cambridge, Mass., appointed Andrew Geall to its scientific advisory board.

X4 Pharmaceuticals Inc., of Cambridge, Mass., appointed Renato Skerlj senior vice president, research and development.

Xenon Pharmaceuticals Inc., of Burnaby, British Columbia, appointed Shelley McCloskey senior vice president, human resources.

Zosano Pharma Corp., of Fremont, Calif., appointed Dushyant Pathak senior vice president of business development.

Zymeworks Inc., of Vancouver, British Columbia, appointed Lota Zoth chair of its board.

No Comments